W W Offen

A simple stopping rule for declaring treatment ineffectiveness in clinical trials.

G G Enas, W W Offen, G. Enas, 1993, Journal of biopharmaceutical statistics.

Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB).

W W Offen, W. Offen, N. Cutler, 1998, Alzheimer disease and associated disorders.

The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease.

W W Offen, S. Paul, S. Paul, 1997, Alzheimer disease and associated disorders.

Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.

W W Offen, A. Levey, S. Gauthier, 1997, Archives of neurology.

A pharmacokinetic profile of nizatidine in man.

W W Offen, W. Offen, G. Aronoff, 1987, Scandinavian journal of gastroenterology. Supplement.